Childhood cancers: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• ABL1 2
• NF1 12
• HER2 25
• PI3K 5
• AKT 1
• PD-L1 13
• CDK4/6 7
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• PSMA 20
• KMT2A 12
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• CD38 5
• EZH2 0
• RAS 1
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

  NCT02728388· Donald Basel· Updated 10 Jul 2026

  “data analysis unequivocal - requires study methodology re-evaluation”Registry text, quoted unchanged. Source

• Terminated

  Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

  NCT05891847· AstraZeneca· Updated 8 Jul 2026

  “Statistically significant failure to achieve key secondary endpoints. The current data do not demonstrate sufficient potential to achieve the planned scientific objectives. The need to optimize the allocation of company resources.”Registry text, quoted unchanged. Source

• Terminated

  US Selumetinib Registry

  NCT05683678· Alexion Pharmaceuticals, Inc.· Updated 4 Apr 2025

  “Sponsor decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Stem Cells in NF1 Patients With Tumors of the Central Nervous System

  NCT03332030· Roger Packer· Updated 7 Feb 2024

  “Suspended due to cessation of funding”Registry text, quoted unchanged. Source

• Withdrawn

  Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study

  NCT05825365· AstraZeneca· Updated 14 Aug 2023

  “Selumetinib launch approval achieved in advance,strategy changesa new study will be generated in place of this study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

  NCT03871257· National Cancer Institute (NCI)· Source

• Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

  NCT04750928· National Cancer Institute (NCI)· Source

• Natural History Study of Patients With Neurofibromatosis Type I

  NCT00924196· National Cancer Institute (NCI)· Source

• Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

  NCT06222203· National Cancer Institute (NCI)· Source

• Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  NCT02390752· National Cancer Institute (NCI)· Source

• Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

  NCT02544022· National Cancer Institute (NCI)· Source

• Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor

  NCT07743554· Girish Dhall, MD· Source

• AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

  NCT01362803· National Cancer Institute (NCI)· Source

• A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

  NCT06507748· National Cancer Institute (NCI)· Source

• A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PNs)

  2025-522000-24-00· Merck Healthcare KGaA· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 520
• Machine Learning 67
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Integrative Multi-Omics and Single-Cell Analyses Identify FKBP10 as a CAF-Associated Biomarker Linked to ECM Remodeling and Aggressiveness in Neuroblastoma.

  Oncol Res, Oct 2026

• Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia.

  Nat Commun, Oct 2026

• Spatial and single-cell dissection of medulloblastoma identifies developmental hierarchies and a prognostic PPIA-BSG tumor-immune axis.

  J Transl Med, Sept 2026

• Integration of Bulk RNA Sequencing and Single-Cell Sequencing to Identify Prognostic Genes Associated With MCDRGs in Neuroblastoma.

  FASEB J, Aug 2026

• Case Report: Single-cell transcriptomic profiling of a pediatric ALK-negative gastric inflammatory myofibroblastic tumor.

  Front Immunol, Aug 2026

• Single-cell chromatin profiling reveals relapse-related priming in pediatric acute myeloid leukemia.

  Life Sci Alliance, Aug 2026

• Ferroptosis-Based Peripheral Immune Dysregulation and Diagnostic Signatures in Parkinson's Disease: An RNA Transcriptomic and Single-Cell Immune Sequencing Analysis.

  FASEB J, Aug 2026

• Improved Surfactant-Assisted One-Pot Sample Preparation for Robust Convenient Single-Cell Proteomics.

  J Proteome Res, Aug 2026

• Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma.

  Sci Adv, Jul 2026

• Single‑cell atlas reveals a Wilms' tumor 1‑mediated axis driving granulosa cell senescence in human ovarian aging.

  Int J Mol Med, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.